Advanced Prostate Cancer | ICHOM – International Consortium for Health Outcomes Measurement

Advanced Prostate Cancer

Advanced Prostate Cancer

Advanced Prostate Cancer

The ICHOM Standard Set for Advanced Prostate Cancer was published in European Urology.


european_urology

The ICHOM Standard Set for Advanced Prostate Cancer is the result of hard work by a group of leading physicians, measurement experts and patients. It is our recommendation of the outcomes that matter most to patients with Advanced Prostate Cancer. We urge all providers around the world to start measuring these outcomes to better understand how to improve the lives of their patients. Advanced Prostate Cancer

1 Recorded via the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0
2 Recorded via the Eastern Cooperative Oncology Group (ECOG) score
3 Includes pain-related quality of life and need for pain medication
4 Includes urinary incontinence, urinary frequency, urinary obstruction, urinary irritation, and bowel irritation
5 Includes hormonal symptoms
6 Recommended to track via the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
7 Recommended to track via the Expanded Prostate Cancer Index Composite (EPIC-26)
8 Includes symptomatic skeletal related event, time to metastasis, castration resistant disease, and procedures needed for local progression


© 2015 ICHOM. All rights reserved. When using this set of outcomes, or quoting therefrom, in any way, we solely require that you always make a reference to ICHOM as the source so that this organization can continue its work to define more standard outcome sets.



Team that developed this standard


Australia

Ian Davis | Monash University; Eastern Health Clinical School
Susan Evans | Monash University
Ian Roos* | Cancer Action Victoria

Belgium

Louis Denis* | Oncology Center Antwerp, US TOO Belgium
Bertrand Tombal | Cliniques Universitaires Saint Luc, Université Catholique de Louvain

Canada

Neil Fleshner | University of Toronto
Andrew Matthew | University of Toronto

France

Alberto Bossi | Gustave Roussy Cancer Institute

Germany

Thomas Steuber | University Hospital Hamburg-Eppendorf

Ireland

Ray McDermott | St. Vincent’s University Hospital

Netherlands

Theo de Reijke | Academic Medical Center Amsterdam
Jean-Paul van Basten | Canisius Wilhelmina Hospital
Koos van der Hoeven | Leiden University Medical Center

Heather Payne | University College Hospitals London

United States

Janet Abrahm | Dana-Farber Cancer Institute
Ethan Basch | University of North Carolina at Chapel Hill
Justin Bekelman | University of Pennsylvania
Donna Berry | Dana-Farber Cancer Institute
Daniel George | Duke University Medical Center
Jim Kiefert* | US TOO
Daniel Lin | University of Washington
Alicia Morgans | Vanderbilt University Medical Center
David Penson | Vanderbilt University Medical Center
Deborah Schrag | Dana-Farber Cancer Institute

*Patient representative

Receive Updates


Reference Guide

A complete overview of the ICHOM Standard Set, including definitions for each measure and selected PROM instruments, time points for collection, and associated risk factors is available here:

dl_ref_guide_apc_3

Version 2.3.1: April 10th, 2017

3 MB

Get the Flyer

2,1 MB

Get the Database

40 KB

How to measure?

Interested in measuring the ICHOM Standard Set? Learn how to measure.